Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial

Journal:

Nature Communications

Published:

2025-08-07

DOI:

10.1038/s41467-025-62509-z

Affiliations:

6

Authors:

19

Go to article

Institutions	Authors	Share
The University of Texas MD Anderson Cancer Center, United States of America (USA)	13.000000 13.000000	0.68
BostonGene, United States of America (USA)	3.000000	0.16
Foresight Diagnostics, United States of America (USA)	1.000000	0.05
University Hospital of Munich (KUM), LMU, Germany	1.000000	0.05
Stanford University, United States of America (USA)	1.000000	0.05

Interested in Cardiovascular Medicine and Haematology?